Recently released in the 2024 Journal Citation Reports™ (JCR) by Clarivate, the Impact Factor of Theranostics has significantly increased to 13.3, marking progressive growth from the previous year's IF of 12.4. This achievement further underscores the journal's prominent position in the fields of translational medicine and precision medicine. According to the JCR 2024, The IF 13.3 of Theranostics not only sets a new historical high for the journal but also firmly places it among the top tier (top 1%) of global medical journals (Medicine category). The journal has consistently demonstrated growth over multiple consecutive years. This accomplishment reflects the high recognition by the global scientific community of the academic quality, innovative value, and international citation impact of the research published in Theranostics.

As a flagship journal in translational medicine, Theranostics is published by the internationally renowned publisher Ivyspring International Publisher and is led by Editor-in-Chief Prof. Xiaoyuan (Shawn) Chen of the National University of Singapore. The journal remains dedicated to publishing original research related to "Theranostics" (diagnosis and therapy integration), covering cutting-edge areas such as molecular imaging, nanomedicine, targeted drug delivery, biomarker development, and AI-assisted diagnosis and therapy. It serves as a high-level platform for interdisciplinary research. Theranostics adheres to an Open Access (OA) publishing model, ensuring immediate and free global access to research findings, this strategy significantly enhances the dissemination efficiency and translational potential of important scientific discoveries. The journal is currently indexed in major global databases including SCI, PubMed, and Scopus, with readers spanning 120+ countries and territories worldwide. Theranostics warmly welcomes submissions of high-quality original research articles, reviews, and perspective papers from researchers worldwide. The journal employs a rapid review mechanism, committed to efficiently serving academic innovation, and stands as one of the most influential academic platforms in the field of translational medicine.